中国临床药理学杂志2013，Vol.29Issue(4)：249-251,3.
伊立替康联合顺铂二线治疗晚期转移性结直肠癌临床对照研究
Clinical study of irinotecan combination with cisplatin vs irinotecan second-line treatment on advanced metastatic colorectal cancer
摘要
Abstract
Objective To evaluate the clinical efficacy and safety of irinotecan combination with cisplatin vs irinotecan second - line treatment on advanced metastatic colorectal cancer. Methods One hundred and forty - three patients with advanced metastasis colorectal cancer were divided in to irinotecan combination with cisplatin group with 74 cases and irinotecan alone with 69 cases. Controls group: irinotecan 250 mg ? m-2 , IVD 90 minutes on day 1. Treatment group; irinotecan 250 mg ? m-2, IVD 90 minutes in day1 and cisplatin 25 mg ? m-2 on day 1 - 3, 21 days per cycle. The rates of response, side effects and long term survival were compared between the two groups. Results The overall response rate( ORR) was 45. 9% (28/61) and 27. 5% (14/51) in the treatment group and control group respectively, which demonstrated significant difference between the two groups (χ2 = 4. 03 P = 0. 045 ). Patients in treatment group had longer median survival time compared with control group(13. 2 vs 8.8 months, HR =0.46,95% CI:0. 29 -0.79, P < 0. 01) compared with control group. Conclusion The treatment of irinotecan combination with cisplatin can significantly improve survival time of advanced metastatic colorectal cancer patients. The main side effects are gastrointestinal and hematological toxicities.关键词
伊立替康/转移性结直肠癌/顺铂Key words
irinotecan/metastatic colorectal cancer/cispiatin分类
医药卫生引用本文复制引用
张斌,刘慧燕..伊立替康联合顺铂二线治疗晚期转移性结直肠癌临床对照研究[J].中国临床药理学杂志,2013,29(4):249-251,3.
